MUSCLE RELAXANT AND ANALGESIC CAPLETS TABLET

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

IBUPROFEN; METHOCARBAMOL

Disponibbli minn:

INTERNATIONAL PHARMACEUTICAL GENERICS LTD

Kodiċi ATC:

M03BA53

INN (Isem Internazzjonali):

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

Dożaġġ:

200MG; 500MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

100

Tip ta 'preskrizzjoni:

OTC

Żona terapewtika:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0248961001; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED PRE MARKET

Data ta 'l-awtorizzazzjoni:

2017-06-13

Karatteristiċi tal-prodott

1 | P a g e
PRODUCT MONOGRAPH
MUSCLE RELAXANT & ANALGESIC CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
INTERNATIONAL PHARMACEUTICAL GENERICS LTD.,
Date of Preparation:
30 Malta Avenue, Suite 2408
February 01, 2010
Brampton, ON
L6Y 4S5
Control#: 135919
2 | P a g e
TABLE
OF CONTENTS
Clinical
Pharmacology..............................................................................................................................3
Indications:................................................................................................................................................7
Contraindications
......................................................................................................................................8
Warnings:..................................................................................................................................................8
Precautions..............................................................................................................................................12
Drug Interactions
....................................................................................................................................13
Adverse Reactions
..................................................................................................................................15
Symptoms and Treatment of
Overdose...................................................................................................17
Dosage and
Administration.....................................................................................................................18
Pharmaceutical
Information....................................................................................................................19
Composition:...........................................................................................................................................21
Availability of Dosage
Forms............